文献速递骨软组织肉瘤与黑色素瘤支持与姑息治疗

体外扩增多肿瘤相关抗原特异性细胞毒性T细胞治疗复发难治性实体瘤的I期研究

Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I Study.
PubMed 文献 · J Clin Oncol · 2019-07-29

这项首次人体I期试验评估了靶向WT1、PRAME和survivin的肿瘤相关抗原特异性细胞毒性T细胞(TAA-T)治疗复发/难治性实体瘤的安全性。15例可评估患者中无剂量限制性毒性,11例(73%)在第45天达到疾病稳定或更好,最高剂量组6个月无进展生存率为73%。TAA-T安全诱导疾病稳定并延长进展时间,且与抗原扩展和循环肿瘤相关抗原DNA水平降低相关。

要点

  • TAA-T治疗复发/难治性实体瘤未出现剂量限制性毒性。
  • 15例可评估患者中11例(73%)第45天达疾病稳定或更好。
  • 最高剂量组6个月无进展生存率73%,优于既往治疗的38%。

核心结论

  • TAA-T安全诱导疾病稳定、延长进展时间,并与抗原扩展和循环肿瘤相关抗原DNA水平降低相关。
  • TAA-T是复发/难治性实体瘤有前景的新治疗方法。

研究设计与样本

  • 首次人体I期试验,TAA-T靶向Wilms瘤基因1、黑色素瘤优先表达抗原和survivin。
  • TAA-T产品由自体外周血生成,三个剂量水平回输:1、2和4×10^7细胞/m2。
  • 患者最多接受八次回输,间隔4至7周;回输后前45天评估剂量限制性毒性。

主要发现

  • 无剂量限制性毒性。
  • 15例可评估患者中,11例(73%)在回输后第45天达疾病稳定或更好,定义为缓解者。
  • 6例缓解者在首次TAA-T后中位13.9个月(范围4.1至19.9个月)仍无进展。
  • 最高剂量组临床结局最佳,TAA-T回输后6个月无进展生存率为73%,既往治疗为38%。
  • 回输后观察到抗原扩展和循环肿瘤相关抗原DNA水平降低(数字液滴PCR检测)。

临床怎么用

  • TAA-T可在不进行淋巴细胞清除化疗的情况下安全回输于复发/难治性实体瘤患者。
  • 最高剂量水平(4×10^7细胞/m2)与最佳临床结局相关,值得进一步研究。

局限性

  • 为I期试验,样本量有限(15例可评估患者),主要评估安全性。
  • 疾病反应在I期试验背景下确定,需更大规模研究验证疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Tumor-associated antigen cytotoxic T cells (TAA-Ts) represent a new, potentially effective and nontoxic therapeutic approach for patients with relapsed or refractory solid tumors. In this first-in-human trial, we investigated the safety of administering TAA-Ts that target Wilms tumor gene 1, preferentially expressed antigen of melanoma, and survivin to patients with relapsed/refractory solid tumors. MATERIALS AND METHODS: TAA-T products were generated from autologous peripheral blood and infused over three dose levels: 1, 2, and 4 × 107 cells/m2. Patients were eligible for up to eight infusions administered 4 to 7 weeks apart. We assessed dose limiting toxicity during the first 45 days after infusion. Disease response was determined within the context of a phase I trial. RESULTS: There were no dose-limiting toxicities. Of 15 evaluable patients, 11 (73%) with stable disease or better at day 45 postinfusion were defined as responders. Six responders remain without progression at a median of 13.9 months (range, 4.1 to 19.9 months) after initial TAA-Ts. Patients who were treated at the highest dose level showed the best clinical outcomes, with a 6-month progression-free survival of 73% after TAA-T infusion compared with a 38% 6-month progression-free survival with prior therapy. Antigen spreading and a reduction in circulating tumor-associated antigens using digital droplet polymerase chain reaction was observed in patients after TAA-T infusion. CONCLUSION: TAA-Ts safely induced disease stabilization, prolonged time to progression, and were associated with antigen spreading and a reduction in circulating tumor-associated antigen DNA levels in patients with relapsed/refractory solid tumors without lymphodepleting chemotherapy before infusion. TAA-Ts are a promising new treatment approach for patients with solid tumors.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hont AB, Cruz CR, Ulrey R, et al. Immunotherapy of Relapsed and Refractory Solid Tumors With Ex Vivo Expanded Multi-Tumor Associated Antigen Specific Cytotoxic T Lymphocytes: A Phase I Study. J Clin Oncol. 2019. PMID: 31356143. doi:10.1200/JCO.19.00177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。